Cash Flow Statement
Growth Metrics

Mimedx (MDXG) EBIT Margin (2011 - 2026)

Mimedx recorded quarterly EBIT Margin of 27.21% in Q1 2026, down 252.44% quarter-over-quarter from 17.85% in Q4 2025, and down 3656.0% year-over-year from 0.77% in Q1 2025.

Mimedx's EBIT Margin history runs 16 years deep, the most recent figure standing at 27.21% for Q1 2026.

  • In Q1 2026, EBIT Margin fell 3656.0% year-over-year to 27.21%; the TTM figure through Mar 2026 stood at 10.17% (down 513.0% YoY), while the FY2025 annual figure was 15.26%, down 161.0% from the prior year.
  • EBIT Margin came in at 27.21% for Q1 2026 at Mimedx, down from 17.85% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 26.89% in Q2 2024 to a low of 27.21% in Q1 2026.
  • A 5-year average of 6.97% and a median of 13.28% in 2024 frame the typical range for EBIT Margin.
  • Across the five-year window, EBIT Margin jumped 2775 bps in 2023 and plunged 3656 bps in 2026, its largest moves.
  • Mimedx's EBIT Margin stood at 15.21% in 2022, then grew by 17 bps to 17.84% in 2023, then sank by 33 bps to 11.9% in 2024, then soared by 50 bps to 17.85% in 2025, then tumbled by 252 bps to 27.21% in 2026.
  • According to Business Quant data, EBIT Margin over the past three periods registered 27.21%, 17.85%, and 19.51% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 38.10%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 17.83%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 23.02%
10 Mimedx 530.69 Mn 370.92 Mn 41.62 Mn -27.21%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -27.21%
Dec 31, 2025 17.85%
Sep 30, 2025 19.51%
Jun 30, 2025 12.55%
Mar 31, 2025 9.35%
Dec 31, 2024 11.90%
Sep 30, 2024 13.28%
Jun 30, 2024 26.89%
Mar 31, 2024 15.58%
Dec 31, 2023 17.84%
Sep 30, 2023 13.61%
Jun 30, 2023 13.34%
Mar 31, 2023 -0.47%
Dec 31, 2022 15.21%
Sep 30, 2022 -10.49%
Jun 30, 2022 -14.41%
Mar 31, 2022 -15.79%
Dec 31, 2021 2.53%
Sep 30, 2021 -1.70%
Jun 30, 2021 -0.60%
Mar 31, 2021 -11.43%
Dec 31, 2020 -23.47%
Sep 30, 2020 -15.10%
Jun 30, 2020 -10.92%
Mar 31, 2020 -22.26%
Dec 31, 2019 -6.38%
Sep 30, 2019 15.98%
Jun 30, 2019 -25.32%
Mar 31, 2019 -20.15%
Dec 31, 2018 -9.66%
Sep 30, 2018 0.43%
Jun 30, 2018 1.76%
Mar 31, 2018 3.53%
Dec 31, 2017 27.30%
Sep 30, 2017 10.53%
Jun 30, 2017 8.96%
Mar 31, 2017 8.99%
Dec 31, 2016 -12.66%
Sep 30, 2016 7.30%
Jun 30, 2016 6.21%
Mar 31, 2016 2.75%
Dec 31, 2015 14.95%
Sep 30, 2015 13.70%
Jun 30, 2015 12.37%
Mar 31, 2015 10.42%
Dec 31, 2014 11.76%
Sep 30, 2014 11.13%
Jun 30, 2014 -1.53%
Mar 31, 2014 -4.56%
Dec 31, 2013 -7.85%
Sep 30, 2013 -1.59%
Jun 30, 2013 -5.51%
Mar 31, 2013 -1.96%
Dec 31, 2012 -9.25%
Sep 30, 2012 -45.70%
Jun 30, 2012 -2.41%
Mar 31, 2012 -17.04%
Dec 31, 2011 -92.43%
Sep 30, 2011 -76.78%
Jun 30, 2011 -125.24%
Mar 31, 2011 -312.06%